Wells Fargo analyst Eva Fortea Verdejo lowered the firm’s price target on iTeos Therapeutics (ITOS) to $13 from $16 and keeps an Overweight rating on the shares. The firm thinks the decision to terminate the TIGIT collaboration is positive for iTeos and waits for further clarity on the company’s strategy moving forward.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- iTeos Therapeutics price target lowered to $12 from $16 at Piper Sandler
- Leerink downgrades iTeos Therapeutics after termination of TIGIT program
- iTeos Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- iTeos Therapeutics downgraded to Market Perform from Outperform at Leerink
- Strategic Shift and Strong Financials Position iTeos Therapeutics for Growth